Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope for women with recurrent pregnancy failure: new drug combo trial

NCT ID NCT07488949

Disease control Sponsor: Fang Wang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether adding medroxyprogesterone acetate to standard doxycycline treatment can better cure chronic endometritis and improve pregnancy outcomes in women with recurrent reproductive failure. One thousand women aged 20-45 will be randomly assigned to receive either the combination or doxycycline alone for 14 days. The researchers will track cure rates, pregnancy rates, and live birth rates to see which approach works best.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxycycline and medroxyprogesterone acetate
What this could lead to
If successful, this could provide a more effective treatment for chronic endometritis, potentially improving pregnancy and live birth rates in women with recurrent reproductive failure.
What could go wrong
This is a single-center trial with no phase designation, and the addition of medroxyprogesterone may not significantly improve outcomes over doxycycline alone. Side effects from the medications are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * women aged 20-45 years; * plans to conceive within 12 months; * chronic endometritis(CE) confirmed by endometrial CD138 immunohistochemistry (IHC); * a diagnosis of recurrent reproductive failure(RRF); * willingness to undergo hysteroscopy and endometrial biopsy; * no contraindications to the study medications. Exclusion Criteria: * acute genital tract infection, gynecologic malignancy, endometrial hyperplasia, or uterine fibroids; * pregnancy or lactation; * contraindications to hysteroscopy or anesthesia; * use of antibiotics, glucocorticoids, estrogens, or progestins within 3 months before trial initiation; * allergy to doxycycline or medroxyprogesterone acetate(MPA); * abnormal semen parameters in the male partner.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic endometritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic endometritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic endometritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lanzhou University Second Hospital

    RECRUITING

    Lanzhou, Gansu, 730030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.